PYXS · Pyxis Oncology Inc. Common Stock
View on chartInsiders & Stakes
| GordonMD Global Investments LP 10% Owner | ▲ Buy | Open Market | 15,541,909 Shares held | 10/1/2026 | View profile |
| Bayer World Investments B.V. | ▼ Sell | Other | 2,742,338 Shares held | 10/13/2021 | View profile |
| Sullivan Lara Chief Executive Officer | ▼ Sell | Open Market | 2,403,882 Shares held | 9/18/2023 | View profile |
| Yanchik Connealy Pamela Chief Financial Officer | ▲ Buy | Open Market | 1,199,143 Shares held | 11/26/2024 | View profile |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 1,118,854 Shares held | 10/13/2021 | View profile |
| Feingold Jay Chief Medical Officer | ▲ Buy | Grant | 730,345 Shares held | 3/24/2023 | View profile |
| Wadhane Jitendra Chief Accounting Officer | ▲ Buy | Grant | 512,882 Shares held | 3/24/2026 | View profile |
| FLAVIN JOHN L | ▲ Buy | Grant | 413,015 Shares held | 3/26/2024 | View profile |
| Cline Darren S Director | ▲ Buy | Grant | 251,405 Shares held | 3/26/2024 | View profile |
| Lewis-Hall Freda C Director | ▲ Buy | Grant | 241,405 Shares held | 3/26/2024 | View profile |
| Civik Thomas Director | ▲ Buy | Grant | 206,186 Shares held | 3/24/2023 | View profile |
| HUMPHREY RACHEL Director | ▼ Sell | Open Market | 81,309 Shares held | 4/21/2025 | View profile |
| Dupont Jakob EVP, Head of R&D | ▼ Sell | Open Market | 38,741 Shares held | 6/30/2026 | View profile |
| Santhosh Palani | ▲ Buy | Grant | 6,000 Shares held | 6/7/2024 | View profile |
| Chin Mark | ▼ Sell | Open Market | 0 Shares held | 4/21/2022 | View profile |
Transaction History
| GordonMD Global Investments LP | ▲ Buy | Open Market | 5,517,000 | — | 10/1/2026 |
| Dupont Jakob | ▲ Buy | Option Exercise | 35,000 | $56K | 6/30/2026 |
| Dupont Jakob | ▼ Sell | Open Market | 35,000 | $107K | 6/30/2026 |
| Wadhane Jitendra | ▲ Buy | Grant | 109,461 | $0 | 3/24/2026 |
| HUMPHREY RACHEL | ▼ Sell | Open Market | 13,896 | $14K | 4/21/2025 |
| HUMPHREY RACHEL | ▼ Sell | Open Market | 200 | $194 | 4/17/2025 |
| HUMPHREY RACHEL | ▼ Sell | Open Market | 1,400 | $1K | 4/14/2025 |
| Yanchik Connealy Pamela | ▲ Buy | Open Market | 5,450 | $11K | 11/26/2024 |
| Yanchik Connealy Pamela | ▲ Buy | Open Market | 83,400 | $163K | 11/26/2024 |
| Santhosh Palani | ▲ Buy | Grant | 6,000 | $0 | 6/7/2024 |
| FLAVIN JOHN L | ▲ Buy | Grant | 35,219 | $0 | 3/26/2024 |
| HUMPHREY RACHEL | ▲ Buy | Grant | 38,741 | $0 | 3/26/2024 |
| Wadhane Jitendra | ▲ Buy | Grant | 131,484 | $0 | 3/26/2024 |
| Dupont Jakob | ▲ Buy | Grant | 38,741 | $0 | 3/26/2024 |
| Cline Darren S | ▲ Buy | Grant | 35,219 | $0 | 3/26/2024 |
| Lewis-Hall Freda C | ▲ Buy | Grant | 35,219 | $0 | 3/26/2024 |
| Yanchik Connealy Pamela | ▲ Buy | Grant | 328,710 | $0 | 3/26/2024 |
| Yanchik Connealy Pamela | ▼ Sell | Tax Withholding | 36,949 | $52K | 11/29/2023 |
| Wadhane Jitendra | ▲ Buy | Grant | 40,000 | $0 | 11/15/2023 |
| Yanchik Connealy Pamela | ▲ Buy | Open Market | 8,000 | $15K | 9/28/2023 |
| Yanchik Connealy Pamela | ▲ Buy | Open Market | 6,426 | $12K | 9/27/2023 |
| Wadhane Jitendra | ▲ Buy | Open Market | 2,500 | $5K | 9/27/2023 |
| Wadhane Jitendra | ▲ Buy | Open Market | 5,000 | $9K | 9/25/2023 |
| Yanchik Connealy Pamela | ▲ Buy | Open Market | 12,000 | $20K | 9/25/2023 |
| Wadhane Jitendra | ▲ Buy | Open Market | 2,500 | $4K | 9/22/2023 |
| Yanchik Connealy Pamela | ▲ Buy | Open Market | 5,000 | $9K | 9/22/2023 |
| Sullivan Lara | ▼ Sell | Open Market | 8,541 | $18K | 9/18/2023 |
| Sullivan Lara | ▼ Sell | Open Market | 100 | $225 | 9/14/2023 |
| Sullivan Lara | ▼ Sell | Open Market | 3,000 | $7K | 9/13/2023 |
| Sullivan Lara | ▼ Sell | Tax Withholding | 184,742 | $394K | 9/13/2023 |
| Sullivan Lara | ▼ Sell | Open Market | 4,917 | $11K | 9/12/2023 |
| Sullivan Lara | ▼ Sell | Open Market | 20,000 | $45K | 9/11/2023 |
| Sullivan Lara | ▲ Buy | Grant | 469,483 | $0 | 9/7/2023 |
| Wadhane Jitendra | ▲ Buy | Grant | 93,896 | $0 | 9/7/2023 |
| Yanchik Connealy Pamela | ▲ Buy | Grant | 187,793 | $0 | 9/7/2023 |
| Sullivan Lara | ▲ Buy | Grant | 703,379 | $0 | 3/24/2023 |
| Yanchik Connealy Pamela | ▲ Buy | Grant | 209,803 | $0 | 3/24/2023 |
| Feingold Jay | ▲ Buy | Grant | 209,803 | $0 | 3/24/2023 |
| Wadhane Jitendra | ▲ Buy | Grant | 29,393 | $0 | 3/24/2023 |
| Wadhane Jitendra | ▲ Buy | Grant | 45,000 | $0 | 3/24/2023 |
| Lewis-Hall Freda C | ▲ Buy | Grant | 139,355 | $0 | 3/24/2023 |
| HUMPHREY RACHEL | ▲ Buy | Grant | 58,064 | $0 | 3/24/2023 |
| FLAVIN JOHN L | ▲ Buy | Grant | 139,355 | $0 | 3/24/2023 |
| Cline Darren S | ▲ Buy | Grant | 139,355 | $0 | 3/24/2023 |
| Civik Thomas | ▲ Buy | Grant | 139,355 | $0 | 3/24/2023 |
| Sullivan Lara | ▲ Buy | Grant | 95,684 | $0 | 1/3/2023 |
| Feingold Jay | ▲ Buy | Grant | 53,931 | $0 | 1/3/2023 |
| Yanchik Connealy Pamela | ▲ Buy | Grant | 43,493 | $0 | 1/3/2023 |
| Chin Mark | ▼ Sell | Open Market | 1,745,761 | $5.3M | 4/21/2022 |
| Yanchik Connealy Pamela | ▲ Buy | Grant | 93,493 | $0 | 4/14/2022 |
| Feingold Jay | ▲ Buy | Grant | 115,931 | $0 | 4/14/2022 |
| Sullivan Lara | ▲ Buy | Grant | 315,273 | $0 | 4/14/2022 |
| FLAVIN JOHN L | ▲ Buy | Grant | 66,831 | $0 | 3/31/2022 |
| Feingold Jay | ▲ Buy | Grant | 306,930 | $0 | 3/31/2022 |
| Sullivan Lara | ▲ Buy | Grant | 742,574 | $0 | 3/31/2022 |
| Civik Thomas | ▲ Buy | Grant | 66,831 | $0 | 3/31/2022 |
| Chin Mark | ▲ Buy | Grant | 66,831 | $0 | 3/31/2022 |
| Cline Darren S | ▲ Buy | Grant | 66,831 | $0 | 3/31/2022 |
| Yanchik Connealy Pamela | ▲ Buy | Grant | 247,524 | $0 | 3/31/2022 |
| Lewis-Hall Freda C | ▲ Buy | Grant | 66,831 | $0 | 3/31/2022 |
| Cline Darren S | ▲ Buy | Open Market | 10,000 | $94K | 12/8/2021 |
| Civik Thomas | ▲ Buy | Open Market | 15,700 | $200K | 11/18/2021 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 450,000 | $7.2M | 10/13/2021 |
| Cormorant Asset Management, LP | ▼ Sell | Other | 668,854 | — | 10/13/2021 |
| Bayer World Investments B.V. | ▼ Sell | Other | 2,742,338 | — | 10/13/2021 |
| FLAVIN JOHN L | ▼ Sell | Other | 2,388 | — | 10/13/2021 |
| Chin Mark | ▼ Sell | Other | 1,433,261 | — | 10/13/2021 |
| Chin Mark | ▲ Buy | Open Market | 312,500 | $5.0M | 10/13/2021 |
| Feingold Jay | ▲ Buy | Grant | 43,750 | $0 | 10/7/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Pyxis Oncology Announces $282.6M Public Offering, Stock Drops
Pyxis Oncology disclosed it will price a public offering of up to $282.6 million, including common stock and warrants. The announcement was followed by a decline in the stock price in pre‑market trading. The company also ended a prior $150 million at‑the‑market offering that had not sold any shares. These moves add to the company’s ongoing effort to fund its Phase 3 development program.
Pyxis Oncology Announces $282.6M Public Offering, Stock Drops. Pyxis Oncology disclosed it will price a public offering of up to $282.6 million, including common stock and warrants. The announcement was followed by a decline in the stock price in pre‑market trading. The company also ended a prior $150 million at‑the‑market offering that had not sold any shares. These moves add to the company’s ongoing effort to fund its Phase 3 development program.